LEVOLEUCOVORIN CALCIUM (levoleucovorin calcium) by Teva is high-dose methotrexate therapy levoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Approved for pernicious anemia, megaloblastic anemia secondary to lack of vitamin b 12, because of the risk of progression of neurologic manifestations despite hematologic remission. First approved in 2016.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
Levoleucovorin calcium is the active isomer of 5-formyl tetrahydrofolic acid, a reduced folate used as a rescue agent after high-dose methotrexate therapy and as an adjunct to fluorouracil in colorectal cancer. It counteracts the toxic effects of folic acid antagonists while enhancing fluorouracil efficacy by stabilizing thymidylate synthase inhibition. The drug is administered intravenously as a powder formulation.
Peak-stage product with modest Part D footprint and moderate competitive pressure (30), indicating stable but specialized market with limited growth opportunities.
High-Dose Methotrexate Therapy Levoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Levoleucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of “one-carbon” moieties.…
Worked on LEVOLEUCOVORIN CALCIUM at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on levoleucovorin offers stability in a mature, specialized oncology support franchise with established protocols and defined customer bases (hospital/oncology centers). Career progression is likely incremental rather than transformational, with emphasis on defensive market management and reimbursement optimization in a niche segment.